Merck spinout nails promising study on hep C vaccine

A group of European investigators working in league with a small biotech spun out of Merck four years ago has claimed an early-stage success with a small human trial that has generated positive efficacy results for an experimental hepatitis C vaccine. By targeting some of the consistent internal mechanisms found behind the ever-changing façade of the hepatitis C virus, researcher at Okairos say that their new vaccine spurred an immune response similar to that seen in people with a strong natural immunity. And they believe that the results warrant further human studies to see how it might fit into future cocktail therapies for the big population of patients. Read at FierceBiotech.com

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.